Biomarkers in Mild Stages of Alzheimer’s disease: Utility in clinical practice and their relation with nutritional and lifestyle factors

Carol Dillon, Patricio Pérez Leguizamon, Silvina Heisecke, Diego M. Castro, Jorge Lopez Camelo, Leandro Lon, Cecilia M. Serrano, Veronica Guelar, Fernando E. Taragano


Background: The use of biomarkers in basic and clinical research as well as in clinical practice has become so common that their presence as primary endpoints in clinical trials is now accepted. A biomarker refers to a broad subcategory of medical signs. The aims of this article are to consider the of use biomarkers in Mild stages of Alzheimer’s disease (AD) in research and clinical settings, in addition to defining their utility in clinical practice relating this with nutritional and lifestyle factors as possible treatment.

Methods: We searched MEDLINE, PubMed, and AgeLine databases using different keywords.

Conclusions: A summary of the utility of biomarkers in AD and nutritional and lifestyle factors used as treatment in mild stages are described.

Key words: Biomarkers, Alzheimer’s disease, Dementia, Utility, Clinical practice, Nutritional

Full Text: [Abstract] [Full Article]

DOI: 10.31989/ffhd.v6i10.299


  • There are currently no refbacks.

Copyright (c) 2016 Carol Dillon